V. Nasca

Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer

A. Scarpa, V. Corbo, G. Tortora, 2021, Journal for ImmunoTherapy of Cancer.

Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification

V. Corbo, G. Tortora, L. Salvatore, 2020, International journal of molecular sciences.

Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer

M. Fakih, R. Miceli, M. Overman, 2023, Journal for ImmunoTherapy of Cancer.

Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture: A case report and review of literature

P. Casali, C. Morosi, S. Stacchiotti, 2022, Frontiers in oncology.

Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade

L. Fornaro, S. Lonardi, F. Pietrantonio, 2023, Journal for ImmunoTherapy of Cancer.

Mytomicin-C, metronomic capecitabine and bevacizumab in patients with unresectable or relapsed Pseudomyxoma Peritonei of appendiceal origin

M. Milione, M. Nannini, F. Morano, 2023, Clinical Colorectal Cancer.

Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies

A. Zaniboni, D. Rossini, G. Masi, 2023, Cancers.